Literature DB >> 20966539

TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

A Fariña-Sarasqueta1, M J E M Gosens, E Moerland, I van Lijnschoten, V E P P Lemmens, G D Slooter, H J T Rutten, A J C van den Brule.   

Abstract

AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy. PATIENTS AND METHODS: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected. The variable number of tandem repeats (VNTR) and the single nucleotide polymorphism (SNP) in the 5'-untranslated region of the TS gene were genotyped.
RESULTS: There was a positive association between tumor T stage and the VNTR genotypes (p=0.05).In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found. However, there was an association between both polymorphisms and age. Among patients younger than 60 years, the patients homozygous for 2R seemed to have a better overall survival, whereas among the patients older than 67 this longer survival was seen by the carriers of other genotypes.
CONCLUSION: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma. However, age appears to modify the effects of TS polymorphisms on survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20966539      PMCID: PMC4605551          DOI: 10.3233/ACP-CLO-2010-0526

Source DB:  PubMed          Journal:  Anal Cell Pathol (Amst)        ISSN: 2210-7177            Impact factor:   2.916


  2 in total

1.  An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.

Authors:  Ying-Chao Wang; Hui-Ping Xue; Zhen-Hua Wang; Jing-Yuan Fang
Journal:  Mol Biol Rep       Date:  2013-05-05       Impact factor: 2.316

2.  Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer.

Authors:  José da Silva Nogueira; Fernando Augusto de Lima Marson; Carmen Sílvia Bertuzzo
Journal:  BMC Res Notes       Date:  2012-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.